合作客戶(hù)/
拜耳公司 |
同濟(jì)大學(xué) |
聯(lián)合大學(xué) |
美國(guó)保潔 |
美國(guó)強(qiáng)生 |
瑞士羅氏 |
相關(guān)新聞Info
-
> 0.01mg是什么精度的天平?超微量天平的稱(chēng)重范圍
> 測(cè)量表面張力/界面張力的儀器有哪些?怎么選
> 表面張力儀的測(cè)試范圍以及測(cè)值精度的意義
> 甜菜堿型兩性表面活性劑與有機(jī)膦酸鹽防垢復(fù)配,有效降低樁西原油體系油-水動(dòng)態(tài)界面張力
> 磁場(chǎng)強(qiáng)度和磁化時(shí)長(zhǎng)對(duì)除草劑溶液表面張力、噴霧霧滴粒徑的影響(一)
> 身體對(duì)稱(chēng)性和表面張力有什么關(guān)系
> W/O型Pickering乳液油水間的界面張力對(duì)乳液穩(wěn)定性的影響
> 不同質(zhì)量濃度、pH、鹽度對(duì)三七根提取物水溶液表面張力的影響(三)
> 低表面界面張力驅(qū)、滲一體化驅(qū)油劑的合成路線
> 合成血液穿透試驗(yàn):表面張力受溫度、表面活性劑影響較大
推薦新聞Info
-
> 單萜萜類(lèi)驅(qū)油劑界面張力、配伍性、降黏效果及破乳效果測(cè)試與篩選(三)
> 單萜萜類(lèi)驅(qū)油劑界面張力、配伍性、降黏效果及破乳效果測(cè)試與篩選(二)
> 單萜萜類(lèi)驅(qū)油劑界面張力、配伍性、降黏效果及破乳效果測(cè)試與篩選(一)
> 紫檀芪的穩(wěn)定性增強(qiáng)型抗氧化劑制作備方及界面張力測(cè)試——結(jié)果與討論、結(jié)論
> 紫檀芪的穩(wěn)定性增強(qiáng)型抗氧化劑制作備方及界面張力測(cè)試—— 引言、材料與方法
> 香豆素取代二乙炔LB膜的組裝、聚合及螺旋結(jié)構(gòu)形成機(jī)制(下)
> 香豆素取代二乙炔LB膜的組裝、聚合及螺旋結(jié)構(gòu)形成機(jī)制(中)
> 香豆素取代二乙炔LB膜的組裝、聚合及螺旋結(jié)構(gòu)形成機(jī)制(上)
> 電鍍液表面張力、接觸角、流速以及壓強(qiáng)等因素對(duì)硅通孔浸潤(rùn)過(guò)程的影響(二)
> 電鍍液表面張力、接觸角、流速以及壓強(qiáng)等因素對(duì)硅通孔浸潤(rùn)過(guò)程的影響(一)
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測(cè)定——結(jié)論、工具書(shū)類(lèi)!
來(lái)源:上海謂載 瀏覽 1854 次 發(fā)布時(shí)間:2021-11-26
結(jié)論
胃腸道pH值和緩沖容量的種間差異是重要的考慮因素,尤其是對(duì)胃腸道給藥的pHresponsive配方和可電離藥物。 因此,兔子和豬的空腸、回腸和近端結(jié)腸具有相對(duì)較高的緩沖容量,而豬遠(yuǎn)端結(jié)腸具有較低的緩沖容量是非常重要的考慮因素。 與人相比,大鼠、兔和豬的近端小腸和升結(jié)腸的液體的滲透壓和表面張力也較高。 胃腸道特征的這些差異導(dǎo)致潑尼松龍?jiān)诖笫篌w內(nèi)的溶解度較高(近端結(jié)腸除外),而潑尼松龍?jiān)谪i和兔體內(nèi)的溶解度與人類(lèi)相當(dāng)。 因此,如果在大鼠的體液中測(cè)量,中性化合物潑尼松龍的溶解度可能被高估。 另一方面,可電離藥物美沙拉秦在兔和豬體內(nèi)的溶解度在小腸中部高于人,在結(jié)腸中低于人,僅在小腸遠(yuǎn)端與人相當(dāng)。 胃腸道環(huán)境的差異,如pH值、緩沖容量、滲透壓和表面張力,導(dǎo)致藥物溶解度的差異。 在兔子和豬中,美沙拉秦的溶解度在沿胃腸道向下移動(dòng)時(shí)發(fā)生顯著變化,這在很大程度上受管腔液的pH值和滲透壓的影響。
工具書(shū)類(lèi)
1. Flaisher-Grinberg S et al. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010; 24: 437–438.
2. Insel TR. From animal models to model animals. Biol Psychiatry 2007; 62: 1337–1339.
3. Hannah-Poquette C et al. Modeling mania: further validation for Black Swiss mice as model animals. Behav Brain Res 2011; 223: 222–226.
4. Calabrese EJ. Gastrointestinal and dermal absorption – interspecies differences. Drug Metab Rev 1984; 15: 1013–1032.
5. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory-animals. Biopharm Drug Dispos 1995; 16: 351–380.
6. McConnell EL et al. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 2008; 60: 63–70.
7. Ward FW, Coates ME. Gastrointestinal pH measurement in rats: influence of the microbial flora, diet and fasting. Lab Anim 1987; 21: 216–222.
8. Smith HW. Observations on the Flora of the alimentary tract of animals and factors affecting its composition. J Pathol Bacteriol 1965; 89: 95–122.
9. Clarysse S et al. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci 2009; 98: 1177–1192.
10. Kalantzi L et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006; 23: 165–176.
11. Fadda HM et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm 2010; 7: 1527– 1532.
12. Merchant HA et al. Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. Eur J Pharm Sci 2011; 42: 3–10.
13. ToxNet. Mesalamine: Toxicology data network (ToxNet). US National Library of Medicine, CASRN: 89-57-6. 2014. (http://toxnet.nlm.nih.gov/cgi-bin/sis/ search2/r?dbs+hsdb:@term+@rn+@ rel+89-57-6, last accessed 25th June 2014).
14. Machatha SG, Yalkowsky SH. Comparison of the octanol/water partition coefficients calculated by ClogP, ACDlogP and KowWin to experimentally determined values. Int J Pharm 2005; 294: 185–192.
15. McConnell EL et al. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 2008; 364: 213–226.
16. Mudie DM et al. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010; 7: 1388– 1405.
17. French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res 1993; 10: 1285–1290.
18. Perez de la Cruz Moreno M et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079–1089. 19. Diakidou A et al. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res 2009; 26: 2141–2151.
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測(cè)定——摘要、介紹
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測(cè)定——材料和方法





